Investment analysts have revised their price targets upwards for six major stocks this week, with one company expected to see an 82% surge. The revised targets include four U.S.-listed companies, with the most significant upgrade forecasted for a biopharmaceutical firm.
What Happened: CNBC Pro conducted a screening for global stocks that have garnered price target upgrades from five or more analysts in the past seven days and exhibit a potential upside of over 25%, the report published on Friday.
The upgraded stocks include Shift4 Payments Inc (NYSE:FOUR), Semtech Corp (NASDAQ:SMTC), Formula One Group, and MacroGenics Inc (NASDAQ:MGNX) from the U.S., along with South Korea’s Hyundai Motor (OTC:HYMTF) and France’s Vusion.
This week, MacroGenics Investment banks raised their price target for the biopharmaceutical company MacroGenics, predicting an 83% upside over the next year. The company’s latest trial data for its vobra-duo drug, which showed a significantly improved safety profile, was cited as a potential catalyst for increased efficacy.
According to the report, "We highlight that an improved safety profile with lower discontinuations and dose reductions could lead to better exposure and consequently ...